XML 108 R64.htm IDEA: XBRL DOCUMENT v3.22.1

Cash and cash equivalents - Additional Information (Details) € in Thousands, $ in Millions		1 Months Ended				6 Months Ended	8 Months Ended	10 Months Ended	12 Months Ended
	Jun. 15, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Jun. 30, 2021 USD ($)	May 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Disclosure of Cash and Cash Equivalents [Line Items]
Decrease in cash and cash equivalents									€ 35,230		€ (84,056)	€ 1,109
Loans repayments									2,833		€ 250	€ 500
EIB Loan
Disclosure of Cash and Cash Equivalents [Line Items]
Loans repayments									3,000
BPI loan
Disclosure of Cash and Cash Equivalents [Line Items]
Loans repayments									500
LianBio, NBTXR3
Disclosure of Cash and Cash Equivalents [Line Items]
Upfront payment received	$ 20.0	€ 16,500	$ 20.0				$ 20.0
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3
Disclosure of Cash and Cash Equivalents [Line Items]
Upfront payment				$ 4.0	$ 2.5	€ 5,400		$ 6.5	€ 5,400	$ 6.5

X

- Definition

The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 45
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_IncreaseDecreaseInCashAndCashEquivalents
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 17
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration Agreement, Upfront Payment Received

+ References

No definition available.

+ Details

Name:	nbx_CollaborationAgreementUpfrontPaymentReceived
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Contractual Commitments, Payment

+ References

No definition available.

+ Details

Name:	nbx_ContractualCommitmentsPayment
Namespace Prefix:	nbx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Disclosure of Cash and Cash Equivalents

+ References

No definition available.

+ Details

Name:	nbx_DisclosureOfCashAndCashEquivalentsLineItems
Namespace Prefix:	nbx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BorrowingsByNameAxis=nbx_BanquePubliqueDInvestissementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: